The Life Sciences Division Equity Research & Stock Reports
- Professional research and all the latest forecasts, valuation opinions and multiples from The Life Sciences Division's expert analysts.
- Real-time updates from analysts following company announcements and other events.
- Near-live share prices, user-friendly dashboard, charting and company content.
Disease Modification in a Spectrum of Severity for Lupus Patients
ImmuPharma is a European, late-stage biotechnology company, focused on delivering major new autoimmune therapies. It is developing the novel drug LupuzorTM (forigerimod) a first-in-class autophagy modulator, a late-stage asset with blockbuster potential, that has already shown itself to be safe across multiple trials in what now amounts to hundreds of lupus (Systemic Lupus Erythematosus, SLE) patients. The drug (LupuzorTM) was previously licensed to Cephalon (now Teva) for US$45m (upfront and option), US$500m in potential milestones and a high double-digit royalty stream before regaining global rights. The heterogeneity of lupus disease can be viewed as a spectrum of severity in patients, thus identifying and classifying the disease itself, opens up the opportunity for ImmuPharma to pivot and drive towards a precision-medicine biomarker approach and to provide a stratified disease approach that could help to improve healthcare economics for payors. We initiate with a BUY rating based on what we believe are strongly oversold shares and a target price of 92p.
28 May 19
The Life Sciences Division Research and Daily Commentaries
Research Tree offers The Life Sciences Division research, providing ongoing coverage of 1 shares. We offer 1 reports from The Life Sciences Division on Research Tree.
Research reports provided by The Life Sciences Division
Companies covered by The Life Sciences Division
Sectors covered by The Life Sciences Division